Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis
Status:
Unknown status
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine
models of colitis. The aim of this study was to evaluate the effect of treatment with local
PPARgamma ligand (rosiglitazone) in distal ulcerative colitis.The patients are treated with
rosiglitazone enema, once a day, for fourteen days. Disease activity was assessed before and
after treatment by endoscopical and clinical activity score.